MedPath

BERLIN-CHEMIE AG

🇧🇬Bulgaria
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.berlin-chemie.de

Clinical Trials

9

Active:7
Completed:2

Trial Phases

1 Phases

Phase 1:3

Drug Approvals

13

NMPA:12
EMA:1

Drug Approvals

Simethicone Emulsion

Product Name
柏西
Approval Number
国药准字HJ20160197
Approval Date
Sep 10, 2024
NMPA

Simethicone Emulsion

Product Name
柏西
Approval Number
国药准字HJ20160184
Approval Date
Sep 10, 2024
NMPA

Brivudine Tablets

Product Name
左代
Approval Number
国药准字HJ20140208
Approval Date
Jun 17, 2024
NMPA

Dapoxetine Hydrochloride Tablet

Product Name
必利劲
Approval Number
国药准字HJ20150564
Approval Date
May 31, 2024
NMPA

Dapoxetine Hydrochloride Tablet

Product Name
必利劲
Approval Number
国药准字HJ20150563
Approval Date
May 31, 2024
NMPA

Levothyroxine Sodium Tablets

Product Name
雷替斯
Approval Number
国药准字HJ20160236
Approval Date
Dec 1, 2020
NMPA

Levothyroxine Sodium Tablets

Product Name
雷替斯
Approval Number
国药准字HJ20160235
Approval Date
Dec 1, 2020
NMPA

Dapoxetine Hydrochloride Tablet

Product Name
必利劲
Approval Number
H20150563
Approval Date
Apr 1, 2020
NMPA

Dapoxetine Hydrochloride Tablet

Product Name
必利劲
Approval Number
H20150564
Approval Date
Apr 1, 2020
NMPA

Brivudine Tablets

Product Name
左代
Approval Number
H20140208
Approval Date
Mar 26, 2020
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (100.0%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.